In the Clinic
Diakonos Research, Ltd. is a clinical stage immuno-oncology company that is developing the next generation of cell-based immunotherapy. Dendritic cells are an integral part of the immune system. The Diakonos Dendritic Cell vaccine platform is designed to be a safe and efficacious adjunct therapy for the treatment of cancer and functions by programming the immune system to specifically recognize and target tumor tissue.
CANINE HEMANGIOSARCOMA (HSA) TRIAL
BRAIN CANCER TRIAL